Skip to main content
Premium Trial:

Request an Annual Quote

Arrayit, DHK Enter Distribution Deal for Genomic Testing in India

NEW YORK (GenomeWeb News) – DHK Medical Products will distribute Arrayit's microarray-based genomic tests in India as part of a three-year deal announced today.

Under the terms of the agreement, DHK will offer Arrayit's tests through a planned expanding of a national network of 800 American Medical Center facilities. Arrayit, based in Sunnyvale, Calif., will offer its Variation Identification Platform microarray technology and blood card collection procedure to provide to patients in India information about their genetic predisposition to ailments such as hypertension, obesity, diabetes, cardiovascular disease, breast and ovarian cancer, and Parkinson's disease.

The technology identifies SNP variants in a patient's DNA. Results will be communicated to patients by DHK doctors, and DHK will provide on-site counseling and treatment options as necessary, the partners said.

Chandigarh, India-based DHK estimated that it will sell 25,000 genomic tests in the first year of the deal, 50,000 in the second, and 100,000 in the third year. Cumulative revenues to Arrayit stemming from the agreement are estimated at $16.8 million.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.